76 results
8-K
EX-99.1
IMVT
Immunovant Inc
20 Dec 23
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
4:37pm
, successfully commercialized; the potential impact of global factors, such as the post-COVID-19 environment, geopolitical tensions, and adverse macroeconomic
8-K
EX-99.1
IMVT
Immunovant Inc
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
authorities, successfully commercialized; the potential impact of global factors, such as the post-COVID-19 environment, geopolitical tensions
8-K
EX-99.1
IMVT
Immunovant Inc
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
, successfully commercialized; the potential impact of global factors, such as the post-COVID-19 environment, geopolitical tensions, and adverse
8-K
EX-99.1
IMVT
Immunovant Inc
10 Aug 23
Results of Operations and Financial Condition
7:10am
of global factors, such as the post-COVID-19 environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business
8-K
EX-99.1
IMVT
Immunovant Inc
12 Feb 24
Results of Operations and Financial Condition
7:02am
-COVID-19 environment, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its
8-K
EX-99.1
xbdiz8e
9 Nov 23
Results of Operations and Financial Condition
7:06am
8-K
EX-99.1
33o42a1 qj
9 Jan 24
Regulation FD Disclosure
8:08am
8-K
EX-99.2
fw5nbtk6d6ay34ez5r
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
424B7
0nyv75avf5jxczpdw
15 Jan 21
Prospectus with selling stockholder info
12:00am
8-K
EX-10.11
kjzcezfd
20 Dec 19
Immunovant Sciences Ltd. Closes Transaction with Health Sciences
5:19pm
8-K
EX-10.13
jekbz 150itf7w
20 Dec 19
Immunovant Sciences Ltd. Closes Transaction with Health Sciences
5:19pm